---
title: 'Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify
  Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment:
  A New Concept'
date: '2023-11-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37947974/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231110170941&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: Residual cancer found in a VAB specimen after NAST always
  corresponds to non-pCR. Residual cancer assumed on routine imaging after NAST corresponds
  to actual residual cancer in about half of patients. Response assessment by VAB
  is not safe for the exclusion of residual cancer. Response assessment by biopsies
  after NAST may allow studying the new concept of extended neoadjuvant treatment
  for patients with residual disease in future ...'
disable_comments: true
---
CONCLUSION: Residual cancer found in a VAB specimen after NAST always corresponds to non-pCR. Residual cancer assumed on routine imaging after NAST corresponds to actual residual cancer in about half of patients. Response assessment by VAB is not safe for the exclusion of residual cancer. Response assessment by biopsies after NAST may allow studying the new concept of extended neoadjuvant treatment for patients with residual disease in future ...